David W Reid

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2163638/publications.pdf

Version: 2024-02-01

137 5,190 39 67
papers citations h-index g-index

137 137 137 6144
all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Airway inflammation, basement membrane thickening and bronchial hyperresponsiveness in asthma. Thorax, 2002, 57, 309-316.	5.6	355
2	The relation between acute changes in the systemic inflammatory response and plasma 25-hydroxyvitamin D concentrations after elective knee arthroplasty. American Journal of Clinical Nutrition, 2011, 93, 1006-1011.	4.7	265
3	The Rise of Non-Tuberculosis Mycobacterial Lung Disease. Frontiers in Immunology, 2020, 11, 303.	4.8	219
4	Acute exacerbation of COPD. Respirology, 2016, 21, 1152-1165.	2.3	213
5	Reticular basement membrane fragmentation and potential epithelial mesenchymal transition is exaggerated in the airways of smokers with chronic obstructive pulmonary disease. Respirology, 2010, 15, 930-938.	2.3	147
6	Reduced Airway Distensibility, Fixed Airflow Limitation, and Airway Wall Remodeling in Asthma. American Journal of Respiratory and Critical Care Medicine, 2001, 164, 1718-1721.	5.6	139
7	Increased Vascular Endothelial Growth Factor and Receptors. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 1201-1207.	5.6	128
8	Pseudomonas aeruginosa Uses Multiple Pathways To Acquire Iron during Chronic Infection in Cystic Fibrosis Lungs. Infection and Immunity, 2013, 81, 2697-2704.	2.2	116
9	Increased airway iron as a potential factor in the persistence of Pseudomonas aeruginosa infection in cystic fibrosis. European Respiratory Journal, 2007, 30, 286-292.	6.7	109
10	Evaluation of epithelial mesenchymal transition in patients with chronic obstructive pulmonary disease. Respiratory Research, $2011, 12, 130$.	3.6	109
11	Iron Deficiency in Cystic Fibrosis. Chest, 2002, 121, 48-54.	0.8	106
12	Biofilm differentiation and dispersal in mucoid Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Microbiology (United Kingdom), 2007, 153, 3264-3274.	1.8	96
13	Iron-binding compounds impair Pseudomonas aeruginosa biofilm formation, especially under anaerobic conditions. Journal of Medical Microbiology, 2009, 58, 765-773.	1.8	94
14	Developing an international <i>Pseudomonas aeruginosa</i> reference panel. MicrobiologyOpen, 2013, 2, 1010-1023.	3.0	94
15	Pseudomonas siderophores in the sputum of patients with cystic fibrosis. BioMetals, 2011, 24, 1059-1067.	4.1	87
16	Virulence gene distribution in clinical, nosocomial and environmental isolates of Pseudomonas aeruginosa. Journal of Medical Microbiology, 2010, 59, 881-890.	1.8	85
17	Corticosteroids for acute severe asthma in hospitalised patients. The Cochrane Library, 2001, , .	2.8	82
18	Airway iron and iron-regulatory cytokines in cystic fibrosis. European Respiratory Journal, 2004, 24, 286-291.	6.7	78

#	Article	IF	Citations
19	Possible anti-inflammatory effect of salmeterol against interleukin-8 and neutrophil activation in asthma <i>in vivo</i> . European Respiratory Journal, 2003, 21, 994-999.	6.7	74
20	Transforming growth factor (TGF) β ₁ and Smad signalling pathways: A likely key to <scp>EMT</scp> â€associated <scp>COPD</scp> pathogenesis. Respirology, 2017, 22, 133-140.	2.3	74
21	Elevated metal concentrations in the CF airway correlate with cellular injury and disease severity. Journal of Cystic Fibrosis, 2014, 13, 289-295.	0.7	71
22	Pyrosequencing reveals transient cystic fibrosis lung microbiome changes with intravenous antibiotics. European Respiratory Journal, 2014, 44, 922-930.	6.7	71
23	A randomized controlled trial of inhaled corticosteroids (ICS) on markers of epithelial–mesenchymal transition (EMT) in large airway samples in COPD: an exploratory proof of concept study. International Journal of COPD, 2014, 9, 533.	2.3	70
24	Effects of inhaled fluticasone on angiogenesis and vascular endothelial growth factor in asthma. Thorax, 2007, 62, 314-319.	5.6	69
25	Iron acquisition by Pseudomonas aeruginosa in the lungs of patients with cystic fibrosis. BioMetals, 2009, 22, 53-60.	4.1	67
26	Targeting iron uptake to control <i>Pseudomonas aeruginosa</i> infections in cystic fibrosis. European Respiratory Journal, 2013, 42, 1723-1736.	6.7	67
27	Basement membrane and vascular remodelling in smokers and chronic obstructive pulmonary disease: a cross-sectional study. Respiratory Research, 2010, 11, 105.	3.6	65
28	Cigarette smoke and platelet-activating factor receptor dependent adhesion of <i>Streptococcus pneumoniae </i> to lower airway cells. Thorax, 2012, 67, 908-913.	5.6	65
29	Oxidative stress and lipid-derived inflammatory mediators during acute exacerbations of cystic fibrosis. Respirology, 2007, 12, 63-69.	2.3	60
30	Shared <i>Pseudomonas aeruginosa</i> genotypes are common in Australian cystic fibrosis centres. European Respiratory Journal, 2013, 41, 1091-1100.	6.7	59
31	Reduced Mucosal Associated Invariant T-Cells Are Associated with Increased Disease Severity and Pseudomonas aeruginosa Infection in Cystic Fibrosis. PLoS ONE, 2014, 9, e109891.	2.5	58
32	Interâ€relationships between airway inflammation, reticular basement membrane thickening and bronchial hyperâ€reactivity to methacholine in asthma; a systematic bronchoalveolar lavage and airway biopsy analysis. Clinical and Experimental Allergy, 2005, 35, 1565-1571.	2.9	52
33	Low Rates of Pseudomonas aeruginosa Misidentification in Isolates from Cystic Fibrosis Patients. Journal of Clinical Microbiology, 2009, 47, 1503-1509.	3.9	52
34	Poor clinical outcomes associated with a multiâ€drug resistant clonal strain of <i>Pseudomonas aeruginosa</i> in the Tasmanian cystic fibrosis population. Respirology, 2008, 13, 886-892.	2.3	51
35	Increased vascular permeability precedes cellular inflammation as asthma control deteriorates. Clinical and Experimental Allergy, 2009, 39, 1659-1667.	2.9	50
36	Angiogenesis: A potentially critical part of remodelling in chronic airway diseases?., 2008, 118, 128-137.		49

#	Article	IF	CITATIONS
37	Vascular remodelling in asthma. Current Opinion in Allergy and Clinical Immunology, 2008, 8, 39-43.	2.3	47
38	Role of lung iron in determining the bacterial and host struggle in cystic fibrosis. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2009, 297, L795-L802.	2.9	45
39	Bacterial cyanogenesis occurs in the cystic fibrosis lung. European Respiratory Journal, 2008, 32, 329-333.	6.7	44
40	<scp><i>P</i></scp> <i>scp><i>entres. Respirology, 2016, 21, 329-337.</i></i>	2.3	43
41	Vessel-Associated Transforming Growth Factor-Beta1 (TGF- \hat{I}^21) Is Increased in the Bronchial Reticular Basement Membrane in COPD and Normal Smokers. PLoS ONE, 2012, 7, e39736.	2.5	42
42	Sputum neutrophils in cystic fibrosis patients display a reduced respiratory burst. Journal of Cystic Fibrosis, 2013, 12, 352-362.	0.7	42
43	Changes in cystic fibrosis mortality in Australia, 1979–2005. Medical Journal of Australia, 2011, 195, 392-395.	1.7	39
44	Bronchoalveolar lavage macrophage and lymphocyte phenotypes in lung transplant recipients. Journal of Heart and Lung Transplantation, 2001, 20, 1064-1074.	0.6	38
45	Clinical trial of community nurse mentoring to improve self-management in patients with chronic obstructive pulmonary disease. International Journal of COPD, 2012, 7, 407.	2.3	38
46	Inhaled corticosteroid normalizes some but not all airway vascular remodeling in COPD. International Journal of COPD, 2016, Volume 11, 2359-2367.	2.3	36
47	Airway epithelial platelet-activating factor receptor expression is markedly upregulated in chronic obstructive pulmonary disease. International Journal of COPD, 2014, 9, 853.	2.3	35
48	Distinctive characteristics of bronchial reticular basement membrane and vessel remodelling in chronic obstructive pulmonary disease (COPD) and in asthma: they are not the same disease. Histopathology, 2012, 60, 964-970.	2.9	34
49	The changing prevalence of pulmonary infection in adults with cystic fibrosis: A longitudinal analysis. Journal of Cystic Fibrosis, 2017, 16, 70-77.	0.7	34
50	Biosignificance of bacterial cyanogenesis in the CF lung. Journal of Cystic Fibrosis, 2010, 9, 158-164.	0.7	33
51	Changes in Airway Histone Deacetylase2 in Smokers and COPD with Inhaled Corticosteroids: A Randomized Controlled Trial. PLoS ONE, 2013, 8, e64833.	2.5	33
52	Airway inflammation and antiâ€protease defences rapidly improve during treatment of an acute exacerbation of COPD. Respirology, 2009, 14, 495-503.	2.3	31
53	Mast cells in COPD airways: relationship to bronchodilator responsiveness and angiogenesis. European Respiratory Journal, 2012, 39, 1361-1367.	6.7	31
54	Anaerobic culture conditions favor biofilm-like phenotypes inPseudomonas aeruginosaisolates from patients with cystic fibrosis. FEMS Immunology and Medical Microbiology, 2006, 48, 373-380.	2.7	30

#	Article	IF	CITATIONS
55	Bronchodilator reversibility, airway eosinophilia and antiâ€inflammatory effects of inhaled fluticasone in COPD are not related. Respirology, 2008, 13, 799-809.	2.3	30
56	Inhaled Antibiotics in Cystic Fibrosis (CF) and Non-CF Bronchiectasis. Seminars in Respiratory and Critical Care Medicine, 2015, 36, 267-286.	2.1	30
57	Efficient zinc uptake is critical for the ability of Pseudomonas aeruginosa to express virulence traits and colonize the human lung. Journal of Trace Elements in Medicine and Biology, 2018, 48, 74-80.	3.0	30
58	High Peripheral Blood Th17 Percent Associated with Poor Lung Function in Cystic Fibrosis. PLoS ONE, 2015, 10, e0120912.	2.5	30
59	Age-dependent inaccuracy of asthma death certification in Northern England, 1991–1992. European Respiratory Journal, 1998, 12, 1079-1083.	6.7	28
60	Management and treatment perceptions among young adults with asthma in Melbourne: The Australian experience from the European Community Respiratory Health Survey. Respirology, 2000, 5, 281-287.	2.3	28
61	Exhaled nitric oxide continues to reflect airway hyperresponsiveness and disease activity in inhaled corticosteroid-treated adult asthmatic patients. Respirology, 2003, 8, 479-486.	2.3	26
62	The social network of cystic fibrosis centre care and shared Pseudomonas aeruginosa strain infection: a cross-sectional analysis. Lancet Respiratory Medicine, the, 2015, 3, 640-650.	10.7	26
63	Iron overload and nitric oxide-derived oxidative stress following lung transplantation. Journal of Heart and Lung Transplantation, 2001, 20, 840-849.	0.6	24
64	Nonpharmacological and pharmacological interventions to prevent or reduce airway remodelling. European Respiratory Journal, 2007, 30, 574-588.	6.7	23
65	Pilot evaluation of web enabled symptom monitoring in cystic fibrosis. Informatics for Health and Social Care, 2013, 38, 354-365.	2.6	23
66	An international, multicentre evaluation and description of Burkholderia pseudomallei infection in cystic fibrosis. BMC Pulmonary Medicine, 2015, 15, 116.	2.0	23
67	Normally suppressing CD40 coregulatory signals delivered by airway macrophages to TH2 lymphocytes are defective in patients with atopic asthma. Journal of Allergy and Clinical Immunology, 2001, 107, 863-870.	2.9	21
68	Molecular analysis of changes in Pseudomonas aeruginosa load during treatment of a pulmonary exacerbation in cystic fibrosis. Journal of Cystic Fibrosis, 2013, 12, 688-699.	0.7	21
69	Expression of Pseudomonas aeruginosa Antibiotic Resistance Genes Varies Greatly during Infections in Cystic Fibrosis Patients. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	21
70	Bronchodilator reversibility in Australian adults with chronic obstructive pulmonary disease. Internal Medicine Journal, 2003, 33, 572-577.	0.8	19
71	Epidemiology of Pseudomonas aeruginosa in a tertiary referral teaching hospital. Journal of Hospital Infection, 2009, 73, 151-156.	2.9	18
72	Assessment of airway inflammation using sputum, BAL, and endobronchial biopsies in current and ex-smokers with established COPD. International Journal of COPD, 2010, 5, 327.	2.3	18

#	Article	IF	CITATIONS
73	Anomalies in T Cell Function Are Associated With Individuals at Risk of Mycobacterium abscessus Complex Infection. Frontiers in Immunology, 2018, 9, 1319.	4.8	18
74	Human epididymis protein 4 (HE4) levels inversely correlate with lung function improvement (delta) Tj ETQq0 0 C	0.7 o.7	erlock 10 Tf ! 18
75	GM-CSF therapy in pulmonary alveolar proteinosis. Thorax, 2002, 57, 837-837.	5 . 6	17
76	BAL eotaxin and IL-5 in asthma, and the effects of inhaled corticosteroid and beta2 agonist. Respirology, 2004, 9, 507-513.	2.3	17
77	Lung health care for Aboriginal and Torres Strait Islander Queenslanders: breathing easy is not so easy. Australian Health Review, 2011, 35, 512.	1.1	17
78	Genomic and phenotypic comparison of environmental and patient-derived isolates of Pseudomonas aeruginosa suggest that antimicrobial resistance is rare within the environment. Journal of Medical Microbiology, 2019, 68, 1591-1595.	1.8	16
79	A double-blind placebo-controlled study of the effect of influenza vaccination on airway responsiveness in asthma. Respiratory Medicine, 1998, 92, 1010-1011.	2.9	15
80	Bronchial hyperresponsiveness and the bronchiolitis obliterans syndrome after lung transplantation. Journal of Heart and Lung Transplantation, 2005, 24, 489-492.	0.6	15
81	Decreased lung capillary blood volume post-exercise is compensated by increased membrane diffusing capacity. European Journal of Applied Physiology, 2004, 93, 96-101.	2.5	14
82	Prospective outcomes in patients with acute exacerbations of chronic obstructive pulmonary disease presenting to hospital: a generalisable clinical audit. Internal Medicine Journal, 2015, 45, 925-933.	0.8	14
83	The Iron-chelator, N,N'-bis (2-hydroxybenzyl) Ethylenediamine-N,N'-diacetic acid is an Effective Colistin Adjunct against Clinical Strains of Biofilm-Dwelling Pseudomonas aeruginosa. Antibiotics, 2020, 9, 144.	3.7	14
84	Pathophysiological Response to SARS-CoV-2 Infection Detected by Infrared Spectroscopy Enables Rapid and Robust Saliva Screening for COVID-19. Biomedicines, 2022, 10, 351.	3.2	14
85	Iron chelation directed against biofilms as an adjunct to conventional antibiotics. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2009, 296, L857-L858.	2.9	13
86	Increased susceptibility of cystic fibrosis airway epithelial cells to ferroptosis. Biological Research, 2021, 54, 38.	3.4	13
87	Airway cell and cytokine changes in early asthma deterioration after inhaled corticosteroid reduction. Clinical and Experimental Allergy, 2007, 37, 1189-1198.	2.9	11
88	Decreased virulence of cystic fibrosis Pseudomonas aeruginosa in Dictyostelium discoideum. Microbiology and Immunology, 2011, 55, 224-230.	1.4	11
89	Tropical Australia is a potential reservoir of non-tuberculous mycobacteria in cystic fibrosis. European Respiratory Journal, 2017, 49, 1700046.	6.7	11
90	Reticular Basement Membrane Vessels Are Increased in COPD Bronchial Mucosa by Both Factor VIII and Collagen IV Immunostaining and Are Hyperpermeable. Journal of Allergy, 2012, 2012, 1-10.	0.7	10

#	Article	IF	Citations
91	Urease production as a marker of virulence in <i>Pseudomonas aeruginosa</i> Biomedical Science, 2014, 71, 175-176.	1.3	10
92	Granulomatous angiitis leading to a pulmonary veno-occlusive disease-like picture. European Respiratory Journal, 2009, 33, 666-669.	6.7	9
93	Chelated iron as an anti- <i>Pseudomonas aeruginosa</i> biofilm therapeutic strategy. Journal of Applied Microbiology, 2009, 106, 1058-1058.	3.1	9
94	Antimicrobial susceptibility testing of cystic fibrosis and non-cystic fibrosis clinical isolates of Pseudomonas aeruginosa: a comparison of three methods. British Journal of Biomedical Science, 2011, 68, 1-4.	1.3	9
95	Cystic fibrosis: ironing out the problem of infection?. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2008, 295, L23-L24.	2.9	8
96	Ivacaftor in severe cystic fibrosis lung disease and a <scp>G</scp> 551 <scp>D</scp> mutation. Respirology Case Reports, 2013, 1, 52-54.	0.6	8
97	Methicillin-resistant Staphylococcus aureus acquisition in healthcare workers with cystic fibrosis: a retrospective cross-sectional study. BMC Pulmonary Medicine, 2016, 16, 78.	2.0	8
98	Scuba diving, swimming and pulmonary oedema. Internal Medicine Journal, 2007, 37, 345-347.	0.8	7
99	Accurate assessment of systemic iron status in cystic fibrosis will avoid the hazards of inappropriate iron supplementation. Journal of Cystic Fibrosis, 2013, 12, 303-304.	0.7	7
100	Use of inhaled corticosteroids in COPD: improving efficacy. Expert Review of Respiratory Medicine, 2016, 10, 339-350.	2.5	7
101	A first step to STOP cystic fibrosis exacerbations. Journal of Cystic Fibrosis, 2017, 16, 529-531.	0.7	7
102	A critical evaluation of the MefarTM dosimeter. European Respiratory Journal, 1999, 14, 430-434.	6.7	6
103	Exhaled NO in diffuse alveolar haemorrhage. Thorax, 2005, 60, 614-615.	5.6	6
104	Preliminary feasibility and modelling of a liquid matrix <i>Dictyostelium discoideum</i> virulence assay for <i>Pseudomonas aeruginosa</i> . British Journal of Biomedical Science, 2016, 73, 51-55.	1.3	6
105	Mutations in the HFE gene can be associated with increased lung disease severity in cystic fibrosis. Gene, 2019, 683, 12-17.	2.2	6
106	COVID-19 in a complex obstetric patient with cystic fibrosis. Infection, Disease and Health, 2020, 25, 239-241.	1.1	6
107	Variation in nebulizer output and weight output from Mefar dosimeter: implications for multicentre studies. European Respiratory Journal, 1997, 10, 2436-2437.	6.7	5
108	Nebulizer calibration using lithium chloride: an accurate, reproducible and user-friendly method. European Respiratory Journal, 1998, 11, 937-941.	6.7	5

#	Article	IF	CITATIONS
109	Populationâ€based study of cystic fibrosis disease severity and haemochromatosis gene mutations. Respirology, 2010, 15, 141-149.	2.3	5
110	Role of Tris-CaEDTA as an adjuvant with nebulised tobramycin in cystic fibrosis patients with Pseudomonas aeruginosa lung infections: A randomised controlled trial. Journal of Cystic Fibrosis, 2021, 20, 316-323.	0.7	4
111	Tolerance and rebound with zafirlukast in patients with persistent asthma. Journal of Negative Results in BioMedicine, 2008, 7, 3.	1.4	3
112	Atypical presentation of acute pancreatitis in a man with pancreatic insufficiency and cystic fibrosis: a case report. Journal of Medical Case Reports, 2010, 4, 275.	0.8	3
113	Molecular detection of <i>Haemophilus influenzae</i> in COPD sputum is superior to conventional culturing methods. British Journal of Biomedical Science, 2012, 69, 37-39.	1.3	3
114	A Cohort Study of Sleep Quality in Adult Patients with Acute Pulmonary Exacerbations of Cystic Fibrosis. Internal Medicine Journal, 2020, , .	0.8	3
115	Microangiopathic haemolytic anaemia and thrombocytopenia following lung volume reduction surgery in a single lung transplant recipient on maintenance tacrolimus (FK506) therapy. Respirology, 2003, 8, 243-245.	2.3	2
116	Management dilemma; a woman with cystic fibrosis and severe lung disease presenting with colonic carcinoma: a case report. Journal of Medical Case Reports, 2008, 2, 384.	0.8	2
117	<scp>ICU</scp> outcomes in cystic fibrosis following invasive ventilation. Respirology, 2013, 18, 585-586.	2.3	2
118	Increased physical activity post-exacerbation is associated with decreased systemic inflammation in cystic fibrosis $\hat{a}\in$ An observational study. Physiotherapy Theory and Practice, 2020, 36, 1457-1465.	1.3	2
119	Sugar sweet and deadly?. Microbiology (United Kingdom), 2009, 155, 665-666.	1.8	2
120	Investigating the Links between Lower Iron Status in Pregnancy and Respiratory Disease in Offspring Using Murine Models. Nutrients, 2021, 13, 4461.	4.1	2
121	Lower Lobe Consolidation and Pyopneumothorax. Chest, 1997, 112, 1117-1119.	0.8	1
122	Revision of BTS guidelines for treatment of asthma. Thorax, 2003, 58, 280-280.	5.6	1
123	Host response to transmissiblePseudomonas aeruginosa. European Respiratory Journal, 2004, 23, 493-494.	6.7	1
124	Airway distensibility in normal and asthmatic subjects and partitioning of the Fowler dead space. Applied Physiology, Nutrition and Metabolism, 2006, 31, 460-466.	1.9	1
125	Biofilm dispersal and exacerbations of cystic fibrosis lung disease. Pediatric Pulmonology, 2006, 41, 1254-1254.	2.0	1
126	Seasonal comparison of energy and nutrient intakes from food diaries completed for a longitudinal study. Proceedings of the Nutrition Society, 2008, 67, .	1.0	1

#	Article	IF	CITATIONS
127	Superior vena cava obstruction due to total implantable venous access devices in cystic fibrosis: Case series and review. Respiratory Medicine CME, 2011, 4, 99-104.	0.1	1
128	Cancer-protective effects of inhaled corticosteroids in COPD are likely related to modification of epithelial activation. European Respiratory Journal, 2019, 54, 1901088.	6.7	1
129	Treatment of pulmonary exacerbations in cystic fibrosis. Therapy: Open Access in Clinical Medicine, 2011, 8, 623-643.	0.2	1
130	Challenges of providing care to adults with cystic fibrosis. , 2014, , 286-303.		1
131	Inhaled Triamcinolone and Chronic Obstructive Pulmonary Disease. New England Journal of Medicine, 2001, 344, 1553-1556.	27.0	0
132	Management of chronic obstructive pulmonary disease in the twenty-first century. Internal Medicine Journal, 2002, 32, 361-361.	0.8	0
133	S89â€Epithelial Mesenchymal Transition (EMT) in Chronic Obstructive Pulmonary Disease (COPD) Airways is Attenuated by Inhaled Corticosteroids (ICS): Abstract S89 Table 1. Thorax, 2012, 67, A43.1-A43.	5.6	0
134	Hemolysis, elevated liver enzymes, and low platelet (HELLP) syndrome in a 26-year-old woman with cystic fibrosis: a case report. Journal of Medical Case Reports, 2012, 6, 134.	0.8	0
135	Centralised versus outreach models of cystic fibrosis care should be tailored to the needs of the individual patient. Internal Medicine Journal, 2020, 50, 232-235.	0.8	0
136	Outcomes of artery embolisation for cystic fibrosis patients with haemoptysis: a 20â€year experience at a major Australian tertiary centre. Internal Medicine Journal, 2021, 51, 1526-1529.	0.8	0
137	Influence of High Altitude on Lung Development and Function. , 2004, , 267-275.		O